Results 201 to 210 of about 21,694,813 (356)

The price of innovation: new estimates of drug development costs.

Journal of Health Economics, 2003
J. DiMasi, R. W. Hansen, H. Grabowski
semanticscholar   +1 more source

Screening for lung cancer: A systematic review of overdiagnosis and its implications

Molecular Oncology, EarlyView.
Low‐dose computed tomography (CT) screening for lung cancer may increase overdiagnosis compared to no screening, though the risk is likely low versus chest X‐ray. Our review of 8 trials (84 660 participants) shows added costs. Further research with strict adherence to modern nodule management strategies may help determine the extent to which ...
Fiorella Karina Fernández‐Sáenz, Laura de la Torre‐Perez, David R Baldwin, Carlijn van der Aalst, Mangesh Thorat, David Ritchie, Andre L Carvalho, Carolina Espina, Ivan Solà, Carlos Canelo‐Aybar, Moira Magdalena Pissinis, Pablo Alonso‐Coello, Ana Carolina Pereira Nunes Pinto   +12 more
wiley   +1 more source

Mitigate Japan's Drug Loss With Model-Informed Drug Development. [PDF]

CPT Pharmacometrics Syst Pharmacol
Imai Y, Akatsu E, Minton SK.
europepmc   +1 more source

Glycosylated LGALS3BP is highly secreted by bladder cancer cells and represents a novel urinary disease biomarker

Molecular Oncology, EarlyView.
Urinary LGALS3BP is elevated in bladder cancer patients compared to healthy controls as detected by the 1959 antibody–based ELISA. The antibody shows enhanced reactivity to the high‐mannose glycosylated variant secreted by cancer cells treated with kifunensine (KIF).
Asia Pece, Giulio Lovato, Ilaria Cela, Arianna Mercatelli, Benedetta Ferro, Jussi Nikkola, Sara Pagotto, Tommaso Grottola, Vincenzo De Laurenzi, Rossella Cicchetti, Antonio Marchetti, Luigi Schips, Rossano Lattanzio, Stefano Iacobelli, Emily Capone, Peter Black, Mads Daugaard, Michele Marchioni, Gianluca Sala   +18 more
wiley   +1 more source

Use of Biomarkers in Drug Development for Regulatory Purposes. [PDF]

Clin Transl Sci
Schuck RN, Sekar V.
europepmc   +1 more source

Molecular mechanism matters: Benefits of mechanistic computational models for drug development

, 2015
Lindsay E. Clegg, Feilim Mac Gabhann
openalex   +1 more source

Membrane transporters in drug development

Nature reviews. Drug discovery, 2010
K. Giacomini, Shiew-Mei Huang, D. Tweedie, L. Benet, K. Brouwer, X. Chu, A. Dahlin, R. Evers, V. Fischer, K. Hillgren, K. Hoffmaster, T. Ishikawa, D. Keppler, R. Kim, Caroline A. Lee, M. Niemi, J. Polli, Y. Sugiyama, P. Swaan, J. Ware, S. Wright, S. Yee, M. Zamek-Gliszczynski, Lei Zhang   +23 more
semanticscholar   +1 more source

CDK11 inhibition induces cytoplasmic p21WAF1 splice variant by p53 stabilisation and SF3B1 inactivation

Molecular Oncology, EarlyView.
CDK11 inhibition stabilises the tumour suppressor p53 and triggers the production of an alternative p21WAF1 splice variant p21L, through the inactivation of the spliceosomal protein SF3B1. Unlike the canonical p21WAF1 protein, p21L is localised in the cytoplasm and has reduced cell cycle‐blocking activity.
Radovan Krejcir, Lukasz Arcimowicz, Lucia Martinkova, Vaclav Hrabal, Filip Zavadil Kokas, Tomas Henek, Martina Kucerikova, Ondrej Bonczek, Pavlina Zatloukalova, Lenka Hernychova, Philip J. Coates, Borivoj Vojtesek, David P. Lane   +12 more
wiley   +1 more source

Has FDA's Drug Development Tools Qualification Program Improved Drug Development? [PDF]

Ther Innov Regul Sci
Yang F, Bousnina I, Madej A, Kalamegham R.   +3 more
europepmc   +1 more source

BOOK REVIEWS : Recent Developments in Cardiovascular Drugs [PDF]

, 1983
William W. Parmley
openalex